Integra guides higher for 2H

Integra LifeSciences sees FY18 organic revenue growth approximately 5.0%  Consistent with prior guidance. “We were pleased with the strong operational performance from both segments in the second quarter, which enabled us to achieve 40% growth in adjusted net income and 130 basis points of adjusted EBITDA margin expansion, compared to the prior year’s quarter,” said Glenn Coleman, Integra’s CFO. “Given the strong momentum we expect in the second half of 2018, we are raising the low-end of our revenue and EPS guidance ranges.”

https://bit.ly/2LEs7Vp